ATE366722T1 - Substituierte pyridin-derivate als entzündungshemmende mittel - Google Patents
Substituierte pyridin-derivate als entzündungshemmende mittelInfo
- Publication number
- ATE366722T1 ATE366722T1 AT98956570T AT98956570T ATE366722T1 AT E366722 T1 ATE366722 T1 AT E366722T1 AT 98956570 T AT98956570 T AT 98956570T AT 98956570 T AT98956570 T AT 98956570T AT E366722 T1 ATE366722 T1 AT E366722T1
- Authority
- AT
- Austria
- Prior art keywords
- substituted pyridine
- diseases
- compounds
- inflammatory agents
- pyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6495397P | 1997-11-07 | 1997-11-07 | |
US09/185,119 US6022884A (en) | 1997-11-07 | 1998-11-03 | Substituted pyridine compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE366722T1 true ATE366722T1 (de) | 2007-08-15 |
Family
ID=26745070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98956570T ATE366722T1 (de) | 1997-11-07 | 1998-11-04 | Substituierte pyridin-derivate als entzündungshemmende mittel |
Country Status (9)
Country | Link |
---|---|
US (4) | US6022884A (de) |
EP (1) | EP1028945B9 (de) |
JP (1) | JP2001522834A (de) |
AT (1) | ATE366722T1 (de) |
AU (1) | AU742442B2 (de) |
CA (1) | CA2307552C (de) |
DE (1) | DE69838070T2 (de) |
ES (1) | ES2290997T3 (de) |
WO (1) | WO1999024404A1 (de) |
Families Citing this family (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9816837D0 (en) * | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
US6693123B2 (en) * | 1995-11-06 | 2004-02-17 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
CN1254335A (zh) * | 1997-04-04 | 2000-05-24 | 辉瑞产品公司 | 烟酰胺衍生物 |
CA2302438A1 (en) * | 1997-05-19 | 1998-11-26 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
US6316479B1 (en) * | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
JP2002507197A (ja) * | 1997-05-30 | 2002-03-05 | ビーエーエスエフ アクチェンゲゼルシャフト | 置換チオピリジン |
TR200001312T2 (tr) | 1997-11-10 | 2000-09-21 | Bristol-Myers Squibb Company | Benzotiyazol protein tirozin kinaz önleyicileri. |
US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
AR015733A1 (es) * | 1998-03-25 | 2001-05-16 | Otsuka Pharma Co Ltd | DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO. |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
WO2000041698A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
ME00275B (me) * | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
EP1140840B1 (de) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1150955A2 (de) * | 1999-02-04 | 2001-11-07 | Millennium Pharmaceuticals, Inc. | G-protein-gekoppelte heptahelikale rezeptor-verbindungen und entspechende anwendungen |
GB9903919D0 (en) * | 1999-02-19 | 1999-04-14 | Darwin Discovery Ltd | Aminophenols and their therapeutic use |
WO2000069823A1 (en) * | 1999-05-12 | 2000-11-23 | Neurosearch A/S | Ion channel modulating agents |
KR100710100B1 (ko) | 1999-04-15 | 2007-04-23 | 브리스톨-마이어스스퀴브컴파니 | 환형 단백질 티로신 키나제 억제제 |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
AU4556800A (en) * | 1999-04-27 | 2000-11-10 | Smithkline Beecham Plc | Novel treatment |
EP1257536A1 (de) * | 2000-01-27 | 2002-11-20 | Cytovia, Inc. | Substituierte nicotinamiden und analoge als caspaseaktivatoren und apoptose-induzierende mittel und ihre verwendung |
US20040087798A1 (en) * | 2000-03-14 | 2004-05-06 | Akira Yamada | Novel amide compounds |
BR0111158A (pt) * | 2000-05-12 | 2004-04-06 | Genzyme Corp | Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente |
US6562807B2 (en) | 2000-06-23 | 2003-05-13 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6706744B2 (en) | 2000-11-17 | 2004-03-16 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US6821960B2 (en) | 2000-11-17 | 2004-11-23 | Noyo Nordisk Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
CA2429426A1 (en) * | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Isoxazole derivatives |
EP1345890A1 (de) | 2000-11-17 | 2003-09-24 | Novo Nordisk A/S | Glucagon-antagonisten/inverse agonisten |
GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
AU2006200813A1 (en) * | 2000-11-24 | 2006-03-16 | Novartis Ag | Naphthalene derivatives |
ATE548031T1 (de) * | 2000-12-18 | 2012-03-15 | Inst Med Molecular Design Inc | Inhibitoren gegen die produktion und freisetzung entzündungfördernder zytokine |
US7141590B2 (en) | 2000-12-29 | 2006-11-28 | Ucb Sa | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
JP2002262119A (ja) * | 2001-02-28 | 2002-09-13 | Sharp Corp | 画像処理装置、画像処理方法、画像処理プログラムを記録した機械読取可能な記録媒体および画像処理プログラム |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
ATE375331T1 (de) | 2001-11-01 | 2007-10-15 | Janssen Pharmaceutica Nv | Amidderivate als inhibitoren der glycogensynthasekinase-3-beta |
PT1450799E (pt) * | 2001-12-03 | 2007-01-31 | Bayer Pharmaceuticals Corp | Compostos de arilureia em combinação com outros agentes citostáticos ou citotóxicos para tratamento de cancros humanos |
US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CA2475818C (en) | 2002-02-11 | 2011-07-19 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
US20030216396A1 (en) * | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
EP2324825A1 (de) * | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Arylharnstoffe mit Angiogenese hemmender Aktivität |
DE10222895A1 (de) * | 2002-05-23 | 2003-12-11 | Bosch Gmbh Robert | Hochdruckspeicher für Kraftstoffeinspritzsysteme mit integriertem Druckregelventil |
AU2003242127A1 (en) * | 2002-06-05 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
JPWO2003103648A1 (ja) * | 2002-06-05 | 2005-10-06 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
EA008622B1 (ru) * | 2002-06-05 | 2007-06-29 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Ингибиторы ассоциированной с иммунитетом протеинкиназы |
EA009051B1 (ru) * | 2002-06-06 | 2007-10-26 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | О-замещенные гидроксиарильные производные |
AU2003242103A1 (en) * | 2002-06-06 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc | Antiallergic agents |
TW200410675A (en) * | 2002-06-10 | 2004-07-01 | Inst Med Molecular Design Inc | An NF-κB activation inhibitor |
WO2003103655A1 (ja) * | 2002-06-10 | 2003-12-18 | 株式会社医薬分子設計研究所 | 癌治療剤 |
EA011707B1 (ru) * | 2002-06-11 | 2009-04-28 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения нейродегенеративных заболеваний |
TW200409629A (en) | 2002-06-27 | 2004-06-16 | Bristol Myers Squibb Co | 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors |
MXPA05001096A (es) | 2002-07-29 | 2005-11-23 | Rigel Pharmaceuticals Inc | Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina. |
UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
GB0222495D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
US7199119B2 (en) * | 2002-10-31 | 2007-04-03 | Amgen Inc. | Antiinflammation agents |
CN100417847C (zh) * | 2002-11-12 | 2008-09-10 | Nok株式会社 | 橡胶状弹性部件 |
EP1572693A1 (de) * | 2002-12-20 | 2005-09-14 | Pharmacia Corporation | Mitogenaktivierte proteinkinaseaktivierte proteinkinase-2-inhibierende verbindungen |
AU2004220234C1 (en) | 2003-02-13 | 2013-01-17 | Msd K.K. | Novel 2-pyridinecarboxamide derivatives |
DE202004021876U1 (de) * | 2003-02-21 | 2012-01-30 | Resmed Limited | Nasale Anordnung |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
US8796250B2 (en) * | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
BR122016015715B8 (pt) * | 2003-07-23 | 2021-05-25 | Bayer Healthcare Llc | composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico |
CN1826120A (zh) * | 2003-07-23 | 2006-08-30 | 幸讬制药公司 | 用于发炎与免疫相关用途的化合物 |
CA2533684A1 (en) * | 2003-07-25 | 2005-02-10 | Amgen Inc. | Substituted pyridones and pyrimidinones with antiinflammatory properties |
JPWO2005012259A1 (ja) * | 2003-07-30 | 2007-09-27 | 興和株式会社 | オステオポンチン産生抑制方法 |
JP4886511B2 (ja) * | 2003-07-30 | 2012-02-29 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 2,4−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法 |
EP1669348A4 (de) * | 2003-09-30 | 2009-03-11 | Eisai R&D Man Co Ltd | Neues antipilzmittel, das eine heterocyclische verbindung enthält |
DE602004021838D1 (de) * | 2003-10-16 | 2009-08-13 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
EP1751139B1 (de) * | 2004-04-30 | 2011-07-27 | Bayer HealthCare LLC | Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs |
US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
CA2573223C (en) | 2004-08-06 | 2013-05-21 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compound |
EP1782811A4 (de) * | 2004-08-09 | 2010-09-01 | Eisai R&D Man Co Ltd | Neues anti-malaria-mittel mit heterozyklischer verbindung |
US20090227799A1 (en) * | 2004-08-09 | 2009-09-10 | Kazutaka Nakamoto | Novel Antimalarial Agent Containing Heterocyclic Compound |
US20060084184A1 (en) * | 2004-10-19 | 2006-04-20 | Renovar Incorporated | Reagents for urine-based immunological assays |
SI1814878T1 (sl) | 2004-11-24 | 2012-06-29 | Rigel Pharmaceuticals Inc | Spojine spiro-2,4-pirimidindiamina in njihova uporaba |
JP2008527043A (ja) | 2005-01-19 | 2008-07-24 | ブリストル−マイヤーズ スクイブ カンパニー | 血栓塞栓障害治療用のp2y1受容体阻害剤としての2−フェノキシ−n−(1,3,4−チアジアゾール−2−イル)ピリジン−3−アミン誘導体および関連化合物 |
US7829585B2 (en) | 2005-03-30 | 2010-11-09 | Eisai R&D Management Co., Ltd. | Antifungal agent containing pyridine derivative |
CA2604551A1 (en) * | 2005-05-03 | 2007-03-08 | Rigel Pharmaceuticals, Inc. | Jak kinase inhibitors and their uses |
PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
TWI385169B (zh) * | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
ZA200804445B (en) | 2005-12-05 | 2009-11-25 | Otsuka Pharma Co Ltd | Diarylether derivatives as antitumor agents |
AU2007211276B2 (en) * | 2006-01-31 | 2013-06-06 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
CA2657606A1 (en) * | 2006-03-08 | 2007-09-13 | Cortria Corporation | Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries |
ES2649564T3 (es) | 2006-03-31 | 2018-01-12 | Novartis Ag | Inhibidores de DGAT |
CA2652926A1 (en) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
AU2007275634B2 (en) * | 2006-07-21 | 2011-01-20 | Novartis Ag | Formulations for benzimidazolyl pyridyl ethers |
EP1894928A1 (de) * | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Fxr bindende heterocyclische verbindungen |
WO2008035726A1 (fr) * | 2006-09-21 | 2008-03-27 | Eisai R & D Management Co., Ltd. | Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant |
UA95978C2 (ru) | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
AR063028A1 (es) | 2006-10-06 | 2008-12-23 | Banyu Pharma Co Ltd | Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen. |
JP2010520291A (ja) * | 2007-03-07 | 2010-06-10 | コンサート ファーマシューティカルズ インコーポレイテッド | 抗狭心症化合物としての重水素化ピペラジン誘導体 |
JP2010527915A (ja) * | 2007-04-26 | 2010-08-19 | アバロン ファーマシューティカルズ,インコーポレイテッド | 多重環化合物及びその用途 |
CA2685194A1 (en) * | 2007-04-27 | 2008-11-13 | Eisai R&D Management Co., Ltd. | Heterocycle-substituted pyridine derivatives salt or crystal thereof |
TW200841879A (en) * | 2007-04-27 | 2008-11-01 | Eisai R&D Man Co Ltd | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same |
EP2170852A1 (de) * | 2007-06-11 | 2010-04-07 | Bristol-Myers Squibb Company | 1,3-dihydroxysubstituierte phenylamide als glucokinaseaktivatoren |
DE102007044277A1 (de) | 2007-09-17 | 2009-03-19 | Grünenthal GmbH | Substituierte Nicotinamid-Verbindungen und deren Verwendung in Arzneimitteln |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
WO2009083553A1 (en) * | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
KR101062376B1 (ko) * | 2008-04-10 | 2011-09-06 | 한국화학연구원 | 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물 |
AU2009252938B2 (en) * | 2008-05-27 | 2012-04-26 | Astrazeneca Ab | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states |
US8188119B2 (en) * | 2008-10-24 | 2012-05-29 | Eisai R&D Management Co., Ltd | Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same |
WO2010059372A2 (en) * | 2008-10-30 | 2010-05-27 | Herbalscience Group, Llc | Tryptase enzyme inhibiting aminopyridines |
US8748623B2 (en) | 2009-02-17 | 2014-06-10 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
US8974286B2 (en) * | 2009-05-22 | 2015-03-10 | Antonio Mariano Parrottino | Combined behavior schedules of reinforcement system |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
CA2774021A1 (en) * | 2009-09-18 | 2011-03-24 | Adolor Corporation | Use of opioid receptor antagonist for gastrointestinal tract disorders |
US8420647B2 (en) | 2010-01-21 | 2013-04-16 | Hoffmann-La Roche Inc. | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
CN102770426B (zh) | 2010-02-05 | 2016-03-23 | 诺瓦提斯公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
PL2563776T3 (pl) * | 2010-04-27 | 2017-01-31 | Calcimedica Inc | Związki, które modulują wewnątrzkomórkowy wapń |
US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CA2797533A1 (en) | 2010-04-27 | 2011-11-10 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CA2803055A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Heteroaryl compounds and compositions as protein kinase inhibitors |
EP2608672B1 (de) | 2010-08-23 | 2020-12-16 | Syntrix Biosystems, Inc. | Aminopyridin- und aminopyrimidincarboxamide als cxcr2-modulatoren |
SG189146A1 (en) | 2010-10-04 | 2013-05-31 | Otsuka Pharma Co Ltd | 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
WO2012085745A1 (en) | 2010-12-23 | 2012-06-28 | Pfizer Inc. | Glucagon receptor modulators |
EA023517B1 (ru) | 2011-02-08 | 2016-06-30 | Пфайзер Инк. | Модуляторы глюкагонового рецептора |
US8987307B2 (en) * | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
CN103732578B (zh) | 2011-07-22 | 2015-08-12 | 辉瑞大药厂 | 喹啉基胰高血糖素受体调节剂 |
JP6150813B2 (ja) | 2011-11-11 | 2017-06-21 | ノバルティス アーゲー | 増殖性疾患の治療方法 |
WO2013078264A1 (en) | 2011-11-23 | 2013-05-30 | Novartis Ag | Pharmaceutical formulations |
WO2013128927A1 (ja) * | 2012-02-29 | 2013-09-06 | 国立大学法人東京医科歯科大学 | 新規アンドロゲン受容体アンタゴニスト |
JP6066806B2 (ja) * | 2012-04-03 | 2017-01-25 | 大塚製薬株式会社 | 医薬 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
WO2015143654A1 (en) * | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
DK3778595T3 (da) | 2015-02-27 | 2021-10-18 | Calcimedica Inc | Pancreatitisbehandling |
WO2017027400A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
US10413534B2 (en) * | 2017-02-13 | 2019-09-17 | Neuralstem, Inc. | Amelioration of certain deficiencies due to stroke |
WO2018231704A1 (en) * | 2017-06-12 | 2018-12-20 | Dow Agrosciences, Llc | 6-bromonicotinamide and processes of preparation |
KR102426921B1 (ko) | 2019-09-24 | 2022-07-29 | 주식회사 이노보테라퓨틱스 | 헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
WO2022195579A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL132603C (de) * | 1964-08-29 | |||
DE1670522C3 (de) * | 1966-05-12 | 1978-08-31 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | Neue Benzylaminopyridine |
DE1670536B2 (de) * | 1966-11-09 | 1975-05-28 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | Neue 2-Anilino-5-acylamino-pyrimidlne |
US3539639A (en) * | 1967-11-22 | 1970-11-10 | Merck & Co Inc | Certain pyridinoxy or pyridine thio-salicyl anilides and n-phenoxy-pyridyl salicylamides |
ES368093A1 (es) * | 1968-07-16 | 1971-07-16 | Degussa | Procedimiento para la preparacion de bencilaminas n-hetero-ciclicamente sustituidas. |
US4002629A (en) * | 1970-11-11 | 1977-01-11 | A. Christiaens Societe Anonyme | Certain pyridine carboxamide derivatives |
GB1368948A (en) * | 1970-11-11 | 1974-10-02 | Manuf Prod Pharma | Pyridine derivatives |
US3980652A (en) * | 1970-11-11 | 1976-09-14 | A. Christiaens Societe Anonyme | 2-(4-Methyl-piperazino)-3 or 5 cyano pyridine |
US3929807A (en) * | 1971-05-10 | 1975-12-30 | Ciba Geigy Corp | 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles |
US4094982A (en) * | 1975-05-15 | 1978-06-13 | Sankyo Company Limited | Pyridine sulfonamides and their use as anticoccidial agents |
DE2655144A1 (de) * | 1976-12-06 | 1978-06-08 | Basf Ag | Substituierte nicotinsaeureamide |
US4149872A (en) * | 1977-07-21 | 1979-04-17 | Shell Oil Company | N-pyridinyl urea and cyclopropanecarboxamide herbicides |
DE2735919A1 (de) * | 1977-08-10 | 1979-02-22 | Boehringer Sohn Ingelheim | Neue 2-pyridyl- und 2-pyrimidylaminobenzoesaeuren |
PT72878B (en) * | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4888047A (en) * | 1985-10-18 | 1989-12-19 | Ici Americas Inc. | Acylaminoaryloxy and arylthio pyrimidines as herbicides |
DE3633485A1 (de) * | 1986-10-02 | 1988-04-07 | Bayer Ag | Substituierte 2-pyri(mi)dyl-2'-pyridyl-(thio)-ether |
DE3708202A1 (de) * | 1987-03-13 | 1988-09-22 | Bayer Ag | Neue thiazolylether- und -thioetherderivate |
DE3737748A1 (de) * | 1987-11-03 | 1989-05-18 | Schering Ag | 3-arylsulfonylamino-1h-1,2,4-triazole, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider und wachstumsregulierender wirkung |
AU611976B2 (en) * | 1987-12-24 | 1991-06-27 | John Wyeth & Brother Limited | Aroyl urea and carbamic acid derivatives of azabicyclo compounds |
DE3804346A1 (de) * | 1988-02-12 | 1989-08-24 | Boehringer Mannheim Gmbh | Tert.-butylphenyl-pyridyl-amide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
WO1991004027A1 (en) * | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
US4959378A (en) * | 1989-10-24 | 1990-09-25 | Hoechst-Roussel Pharmaceuticals Inc. | Aminopyridinylaminophenol compounds useful as topical antiinflammatory agents for the treatment of skin disorders |
JPH04364168A (ja) * | 1990-08-08 | 1992-12-16 | Taisho Pharmaceut Co Ltd | スルホンアミドピリジン化合物 |
ATE167473T1 (de) * | 1990-08-20 | 1998-07-15 | Eisai Co Ltd | Sulfonamid-derivate |
DE4032147A1 (de) * | 1990-10-10 | 1992-04-16 | Bayer Ag | Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung |
AU645159B2 (en) * | 1991-01-17 | 1994-01-06 | Ici Pharma | Sulphonamide derivatives |
JPH06135934A (ja) * | 1991-12-27 | 1994-05-17 | Ishihara Sangyo Kaisha Ltd | ピリジン誘導体又はその塩を含有するホスホリパーゼ▲a2▼阻害剤、抗炎症剤又は抗膵炎剤 |
IL104369A0 (en) * | 1992-01-13 | 1993-05-13 | Smithkline Beecham Corp | Novel compounds and compositions |
DE4219247A1 (de) * | 1992-06-12 | 1993-12-16 | Bayer Ag | Verwendung von 3-arylsubstituierten 5-Alkyl-isoxazol-4-carbonsäurederivaten zur Bekämpfung von Endoparasiten, neue 3-arylsubstituierte 5-Alkyl-isoxazol-4-carbonsäurederivate und Verfahren zu ihrer Herstellung |
US5312820A (en) * | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
US5380734A (en) * | 1993-04-15 | 1995-01-10 | American Home Products Corporation | N-cyanoamidine derivatives as anti-influenza agents |
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
US5530000A (en) * | 1993-12-22 | 1996-06-25 | Ortho Pharmaceutical Corporation | Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors |
GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
JPH07285962A (ja) * | 1994-04-20 | 1995-10-31 | Nissan Chem Ind Ltd | ピリジンカルボン酸アミド誘導体 |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
GB9420999D0 (en) * | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
WO1996018617A1 (en) * | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase |
WO1996018616A1 (en) * | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
DE69531956T2 (de) * | 1994-12-13 | 2004-07-29 | F. Hoffmann-La Roche Ag | Imidazol derivate mit proteinkinase, insbesondere egf-r tyrosinkinase, inhibierender wirkung |
JPH08175993A (ja) * | 1994-12-21 | 1996-07-09 | Green Cross Corp:The | 抗酸化剤 |
JPH08175995A (ja) * | 1994-12-21 | 1996-07-09 | Green Cross Corp:The | 糖化蛋白変成物質生成阻害剤 |
EP0802908A4 (de) * | 1995-01-12 | 2001-04-11 | Smithkline Beecham Corp | Neue verbindungen |
US5990133A (en) * | 1995-02-02 | 1999-11-23 | Smithkline Beecham P.L.C. | Indole derivatives as 5-HT receptor antagonist |
US5686470A (en) * | 1995-02-10 | 1997-11-11 | Weier; Richard M. | 2, 3-substituted pyridines for the treatment of inflammation |
US5596008A (en) * | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
IL118544A (en) * | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
GB9511694D0 (en) * | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
ATE235239T1 (de) * | 1995-08-10 | 2003-04-15 | Merck & Co Inc | 2-substituierte aryl-pyrrolen, zusammensetzungen solche verbindungen enthaltend und deren verwendung |
EP0871444A4 (de) * | 1995-08-10 | 1999-01-13 | Merck & Co Inc | 2,5 substituierte aryl pyrrol, dieses enthaltende zusammensetzungen und dessen verwendung |
CA2230894A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
WO1997016441A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
WO1997016442A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
WO1997016426A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted aryl pyrroles, compositions containing such compounds and methods of use |
US5617058A (en) * | 1995-11-13 | 1997-04-01 | Apogee Technology, Inc. | Digital signal processing for linearization of small input signals to a tri-state power switch |
TW366261B (en) * | 1996-04-02 | 1999-08-11 | Nihon Nohyaku Co Ltd | Pyridine-2,3-dicarboxylic acid diamide derivatives and herbicides comprising said derivatives as active ingredient |
-
1998
- 1998-11-03 US US09/185,119 patent/US6022884A/en not_active Expired - Fee Related
- 1998-11-04 ES ES98956570T patent/ES2290997T3/es not_active Expired - Lifetime
- 1998-11-04 EP EP98956570A patent/EP1028945B9/de not_active Expired - Lifetime
- 1998-11-04 WO PCT/US1998/023510 patent/WO1999024404A1/en active IP Right Grant
- 1998-11-04 CA CA002307552A patent/CA2307552C/en not_active Expired - Fee Related
- 1998-11-04 AT AT98956570T patent/ATE366722T1/de not_active IP Right Cessation
- 1998-11-04 DE DE69838070T patent/DE69838070T2/de not_active Expired - Fee Related
- 1998-11-04 AU AU13065/99A patent/AU742442B2/en not_active Ceased
- 1998-11-04 JP JP2000520418A patent/JP2001522834A/ja not_active Withdrawn
-
1999
- 1999-11-01 US US09/431,410 patent/US6184237B1/en not_active Expired - Fee Related
-
2000
- 2000-08-21 US US09/642,860 patent/US6333341B1/en not_active Expired - Fee Related
-
2001
- 2001-08-17 US US09/932,281 patent/US6458813B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6458813B1 (en) | 2002-10-01 |
EP1028945A1 (de) | 2000-08-23 |
EP1028945B9 (de) | 2009-02-18 |
WO1999024404A1 (en) | 1999-05-20 |
EP1028945B1 (de) | 2007-07-11 |
JP2001522834A (ja) | 2001-11-20 |
AU1306599A (en) | 1999-05-31 |
AU742442B2 (en) | 2002-01-03 |
DE69838070T2 (de) | 2007-10-25 |
CA2307552C (en) | 2004-06-08 |
CA2307552A1 (en) | 1999-05-20 |
US6333341B1 (en) | 2001-12-25 |
US6022884A (en) | 2000-02-08 |
DE69838070D1 (de) | 2007-08-23 |
US6184237B1 (en) | 2001-02-06 |
ES2290997T3 (es) | 2008-02-16 |
US20020035094A1 (en) | 2002-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE366722T1 (de) | Substituierte pyridin-derivate als entzündungshemmende mittel | |
ATE389636T1 (de) | Substituierte pyridin- und pyridazinderivate und ihre pharmazeutische verwendung | |
PT948495E (pt) | Agentes anti-inflamatorios de pirrolo fundido substituidos em arilo e heteroarilo | |
PT1448564E (pt) | Composto do tipo indolizina substituidos e metodos de utilizacao | |
ATE320426T1 (de) | Harnstoffderivate und ihre verwendung | |
FI20115753A (fi) | Farmaseuttisia koostumuksia IL-6:n tuoton aiheuttamien sairauksien hoitoon | |
WO1998024782A3 (en) | Substituted pyrimidine compounds and their use | |
IS8175A (is) | Píperasín afleiður og aðferðir við notkun þeirra | |
CA2274093A1 (en) | Substituted pyrimidinone and pyridinone compounds and their use | |
ES2191069T3 (es) | Diaril-2-(5h)-furanonas como inhibidores de cox-2. | |
DE602004015810D1 (de) | Substituierte isochinolinderivate und anwendungsverfahren | |
EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
WO2006041888A3 (en) | Substituted aryl or heteroarylsulfonylbutanamides for use as anti-inflammatory agents | |
CA2274063A1 (en) | Substituted pyrimidine compounds and their use | |
ATE355287T1 (de) | 2-oxo-1,3,4-trihydrochinazolin derivative zur behandlung von zellproliferationskrankheiten | |
ATE233244T1 (de) | Carboxylsäure substituierte heterocyclische verbindungen als metalloproteinase inhibitoren | |
EP1314732A3 (de) | Substituierte Pyrimidinverbindungen und ihre Verwendung | |
AR022292A1 (es) | Succinoilamino benzodiazepinas como inhibidoras de la produccion de proteinas a beta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |